ASRA’s cancer pain programming highlights opportunities for pharmacists to individualize opioid therapy, improve medication transitions, and connect patients with evidence-based complementary care.
Commentary|Podcasts|September 7, 2023
Public Health Matters - Current Issues in Oncology Space
Christina Madison, PharmD, FCCP, AAHIVP, speaks with Ryan Haumschild, PharmD, MS, MBA, to discuss current issues in oncology, including drug shortages and patient access.
Advertisement
On this episode of Public Health Matters, Christina Madison, PharmD, FCCP, AAHIVP, spoke with Ryan Haumschild, PharmD, MS, MBA, to discuss current issues in oncology, including drug shortages and patient access.
Ryan Haumschild, PharmD, MS, MBA, is the director of pharmacy services at Emory Healthcare and Winship Cancer Institute in Atlanta, Georgia.
Advertisement
Related to this article
The once-daily oral CSF-1R inhibitor was approved based on the phase 3 MANEUVER trial, which showed gains in tumor response, pain, and joint function.
On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
4
The Most Accessible Healthcare Professional—But Accessible to Whom?
5